ENVB — Enveric Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $3.24m
- -$0.52m
- 10
- 41
- 17
- 11
Annual cashflow statement for Enveric Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.86 | -49 | -18.5 | -17.3 | -9.57 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 3.22 | 35.7 | 1.21 | 3.03 | 1.93 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.369 | 1.19 | -0.218 | -0.175 | -0.423 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.89 | -11.5 | -17.1 | -14.1 | -7.73 |
| Capital Expenditures | — | -0.865 | -0.584 | -0.005 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.044 | 3.06 | 0 | 0.017 | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.044 | 2.19 | -0.584 | 0.012 | — |
| Financing Cash Flow Items | 3.37 | 0 | 0.958 | -0.291 | -0.182 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.53 | 24.9 | 18.2 | -1.34 | 7.67 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.53 | 15.8 | 0.368 | -15.4 | -0.047 |